Logo image of BYAH

PARK HA BIOLOGICAL TECHNOLOG (BYAH) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BYAH - KYG6925R1020 - Common Stock

0.1701 USD
+0.01 (+6.98%)
Last: 1/2/2026, 8:02:56 PM
Fundamental Rating

3

Taking everything into account, BYAH scores 3 out of 10 in our fundamental rating. BYAH was compared to 122 industry peers in the Specialty Retail industry. BYAH has a great financial health rating, but its profitability evaluates not so good. BYAH is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

BYAH had negative earnings in the past year.
BYAH had a positive operating cash flow in the past year.
BYAH Yearly Net Income VS EBIT VS OCF VS FCFBYAH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 500K 1M

1.2 Ratios

BYAH has a worse Return On Assets (-331.89%) than 96.72% of its industry peers.
The Return On Equity of BYAH (-455.43%) is worse than 79.51% of its industry peers.
Industry RankSector Rank
ROA -331.89%
ROE -455.43%
ROIC N/A
ROA(3y)20.25%
ROA(5y)N/A
ROE(3y)81.07%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BYAH Yearly ROA, ROE, ROICBYAH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 20 40 60 80 100

1.3 Margins

With an excellent Gross Margin value of 92.99%, BYAH belongs to the best of the industry, outperforming 98.36% of the companies in the same industry.
BYAH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 92.99%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BYAH Yearly Profit, Operating, Gross MarginsBYAH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 20 40 60 80

7

2. Health

2.1 Basic Checks

BYAH does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BYAH has been reduced compared to 1 year ago.
There is no outstanding debt for BYAH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BYAH Yearly Shares OutstandingBYAH Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 5M 10M 15M 20M 25M
BYAH Yearly Total Debt VS Total AssetsBYAH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 1M 2M 3M

2.2 Solvency

Based on the Altman-Z score of 1.38, we must say that BYAH is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of BYAH (1.38) is worse than 65.57% of its industry peers.
There is no outstanding debt for BYAH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 1.38
ROIC/WACCN/A
WACC8.4%
BYAH Yearly LT Debt VS Equity VS FCFBYAH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 500K 1M 1.5M

2.3 Liquidity

BYAH has a Current Ratio of 3.68. This indicates that BYAH is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of BYAH (3.68) is better than 91.80% of its industry peers.
A Quick Ratio of 3.63 indicates that BYAH has no problem at all paying its short term obligations.
BYAH's Quick ratio of 3.63 is amongst the best of the industry. BYAH outperforms 96.72% of its industry peers.
Industry RankSector Rank
Current Ratio 3.68
Quick Ratio 3.63
BYAH Yearly Current Assets VS Current LiabilitesBYAH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 500K 1M 1.5M 2M 2.5M

1

3. Growth

3.1 Past

The earnings per share for BYAH have decreased strongly by -2189.24% in the last year.
The Revenue has grown by 9.33% in the past year. This is quite good.
EPS 1Y (TTM)-2189.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38931.58%
Revenue 1Y (TTM)9.33%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%45.29%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BYAH Yearly Revenue VS EstimatesBYAH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 500K 1M 1.5M 2M

1

4. Valuation

4.1 Price/Earnings Ratio

BYAH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BYAH Price Earnings VS Forward Price EarningsBYAH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

BYAH's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 37.04
EV/EBITDA N/A
BYAH Per share dataBYAH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.02 -0.04 -0.06 -0.08

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

BYAH does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

PARK HA BIOLOGICAL TECHNOLOG

NASDAQ:BYAH (1/2/2026, 8:02:56 PM)

0.1701

+0.01 (+6.98%)

Chartmill FA Rating
GICS IndustryGroupConsumer Discretionary Distribution & Retail
GICS IndustrySpecialty Retail
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.35%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap5.76M
Revenue(TTM)3.62M
Net Income(TTM)-19.36M
AnalystsN/A
Price TargetN/A
Short Float %0.98%
Short Ratio0.43
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.14
P/FCF 37.04
P/OCF 34.34
P/B 9.49
P/tB 9.51
EV/EBITDA N/A
EPS(TTM)-0.1
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0
FCFY2.7%
OCF(TTM)0
OCFY2.91%
SpS0.02
BVpS0.02
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -331.89%
ROE -455.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 92.99%
FCFM 30.07%
ROA(3y)20.25%
ROA(5y)N/A
ROE(3y)81.07%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)99.2%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 318.59%
Cap/Sales 2.37%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.68
Quick Ratio 3.63
Altman-Z 1.38
F-Score5
WACC8.4%
ROIC/WACCN/A
Cap/Depr(3y)176.35%
Cap/Depr(5y)N/A
Cap/Sales(3y)1.71%
Cap/Sales(5y)N/A
Profit Quality(3y)314.24%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2189.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38931.58%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)9.33%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%45.29%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1586.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y742.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y659.29%
OCF growth 3YN/A
OCF growth 5YN/A

PARK HA BIOLOGICAL TECHNOLOG / BYAH FAQ

Can you provide the ChartMill fundamental rating for PARK HA BIOLOGICAL TECHNOLOG?

ChartMill assigns a fundamental rating of 3 / 10 to BYAH.


Can you provide the valuation status for PARK HA BIOLOGICAL TECHNOLOG?

ChartMill assigns a valuation rating of 1 / 10 to PARK HA BIOLOGICAL TECHNOLOG (BYAH). This can be considered as Overvalued.


Can you provide the profitability details for PARK HA BIOLOGICAL TECHNOLOG?

PARK HA BIOLOGICAL TECHNOLOG (BYAH) has a profitability rating of 1 / 10.